Trial Profile
A randomised, controlled, open-label trial to compare brachial artery reactivity and cardiovascular risk of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination therapy containing DRV/r in HIV-1 infected subjects with undetectable plasma HIV-1 RNA on their current treatments.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2012
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 08 Aug 2011 New trial record